Clinical Trials on Stage I Squamous Cell Carcinoma of the Larynx

Total 2470 results

GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Washington University School of Medicine
Tilde Sciences

Recruiting

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Cancer of the Head and Neck

United States
Aveta Biomics, Inc.

Recruiting

Safety and Efficacy of APG-157 in Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of Oral Cavity

United States
Bristol-Myers Squibb

Completed

A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) (VOLUME-PRO)

Squamous Cell Carcinoma of the Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center

Completed

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Incyte Corporation
Bristol-Myers Squibb

Withdrawn

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Head and Neck Cancer
Genentech, Inc.

Completed

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Head and Neck Cancer

United States, Germany, Spain, France, Australia, Hungary, Belgium, Bulgaria, United Kingdom, Italy, Romania
Groupe Oncologie Radiotherapie Tete et Cou

Recruiting

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01)

Squamous Cell Carcinoma of the Head and Neck

France
Dana-Farber Cancer Institute
National Comprehensive Cancer Network

Completed

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
University of Michigan Rogel Cancer Center
National Institutes of Health (NIH)

Active, not recruiting

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
University of Arkansas

Withdrawn

Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy

Squamous Cell Carcinoma of the Head and Neck

United States
Celgene

Terminated

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Squamous Cell Carcinoma of the Head and Neck

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Recurrent Melanoma | Stage IV Melanoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Stage IIIB Melanoma | Stage IIIC Melanoma | Basal Cell Carcinoma of the Skin | Eccrine Carcinoma...

United States
Medical University of South Carolina

Recruiting

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)

Head and Neck Cancer

Italy, United States, Israel, Japan, Australia, Austria, Brazil, France, Germany, Greece, Ireland, Korea, Republic of, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
University of Cincinnati

Terminated

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Oncolytics Biotech

Completed

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Carcinoma, Squamous Cell of the Head and Neck

United States, Canada, Spain, Belgium, United Kingdom, Greece, Germany, Hungary, Poland, Slovenia, France, Italy, Russian Federation
Thomas Jefferson University
National Cancer Institute (NCI)

Completed

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer... and other conditions

United States
Oncolytics Biotech

Completed

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Carcinoma, Squamous Cell of the Head and Neck

United States
University of Alabama at Birmingham
Aventis Pharmaceuticals

Completed

Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neck Neoplasms

United States
Incyte Corporation

Active, not recruiting

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Squamous Cell Carcinoma of the Anal Canal

United States, Italy, Spain, United Kingdom, Australia, France, Germany, Sweden, Japan, Norway, Belgium, Denmark, Puerto Rico
University Health Network, Toronto
Mirati Therapeutics Inc.

Completed

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth

Canada
Stanford University
National Cancer Institute (NCI)

Terminated

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
AHS Cancer Control Alberta
Cross Cancer Institute; Tom Baker Cancer Centre

Recruiting

p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) (PROTEcT)

Squamous Cell Carcinoma of the Oropharynx

Canada
Oncolytics Biotech
University of Texas

Completed

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

United States
Merck Sharp & Dohme LLC

Terminated

Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

Head and Neck Neoplasms | Carcinoma, Squamous Cell
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States
Jennifer Choe
Arcus Biosciences, Inc.

Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United States
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
Rahul Aggarwal
Xynomic Pharmaceuticals, Inc.

Completed

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial... and other conditions

United States
Tata Memorial Hospital

Unknown

Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

India
Gliknik Inc.

Completed

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

United States, Hungary, Ukraine, Russian Federation, Serbia, Poland, Spain
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
AHS Cancer Control Alberta
EMD Serono

Active, not recruiting

Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)

Squamous Cell Carcinoma of the Cervix | Cancer That is Associated With a Chronic Viral Infection | p16 Positive SCCHN | p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva | p16 Positive Squamous Cell Carcinoma of the Penis | p16 Positive Squamous Cell Carcinoma of the Anus or Anal... and other conditions

Canada
Centre Hospitalier Universitaire de Saint Etienne

Terminated

Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx

Squamous Cell Carcinoma of the Oropharynx

France
Genmab

Completed

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United Kingdom, Belgium, Slovakia, Hungary
Genmab

Completed

Zalutumumab in Head and Neck Cancer

Head and Neck Neoplasms

Denmark, Sweden
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (CisFRad)

Squamous Cell Carcinoma of the Head and Neck

France
Neal Ready
Amgen

Terminated

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN (TOP0901)

Squamous Cell Carcinoma of the Head and Neck

United States
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
National Baromedical Services
Mayo Clinic; Dartmouth-Hitchcock Medical Center; CISSS de Chaudière-Appalaches; Memorial Hermann Hospital and other collaborators

Not yet recruiting

Hyperbaric Radiation Sensitization of Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Akamis Bio
Bristol-Myers Squibb; Syneos Health

Completed

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (SPICE)

Colorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Epithelial Tumor

United States
Turku University Hospital

Completed

Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

Finland
University Hospital, Caen

Completed

Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection (TEPVAD)

Squamous Cell Carcinoma of the Head and Neck

France
Washington University School of Medicine

Withdrawn

Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device

Squamous Cell Carcinoma of the Head and Neck

United States
Providence Health & Services
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States

Clinical Trials on Stage I Squamous Cell Carcinoma of the Larynx

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations